We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

61 hedge funds and large institutions have $38.9M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

15% less funds holding

Funds holding: 72 → 61 (-11)

54% less capital invested

Capital invested by funds: $84.6M → $38.9M (-$45.7M)

56% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 18

Holders
61
Holders Change
-11
Holders Change %
-15.28%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
14
Reduced
16
Closed
18
Calls
$11K
Puts
–
Net Calls
+$11K
Net Calls Change
+$104K

Top Buyers

Rank Fund Capital Flow
1
SG Americas Securities
SG Americas Securities
New York
+$395K
2
BlackRock
BlackRock
New York
+$122K
3
Bank of America
Bank of America
North Carolina
+$53.2K
4
FA
Forefront Analytics
Pennsylvania
+$46.2K
5
GCP
GSA Capital Partners
United Kingdom
+$34.8K

Top Sellers

Rank Fund Capital Flow
1
Artisan Partners
Artisan Partners
Wisconsin
-$4.39M
2
PIM
Platinum Investment Management
Australia
-$1.76M
3
CA
CHI Advisors
New York
-$1.12M
4
Two Sigma Investments
Two Sigma Investments
New York
-$716K
5
New York State Common Retirement Fund
New York State Common Retirement Fund
New York
-$620K
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
26
Legal & General Group
United Kingdom
$58K – – –
Verition Fund Management
27
Verition Fund Management
Connecticut
$36K -$10 -1 -0%
Goldman Sachs
28
Goldman Sachs
New York
$26K -$35.8K -3,654 -50%
HF
29
HRT Financial
New York
$18K +$25.5K +2,599 New
Geode Capital Management
30
Geode Capital Management
Massachusetts
$18K +$25.6K +2,608 New
BCV
31
Banque Cantonale Vaudoise
Switzerland
$17K – – –
AWM
32
Altium Wealth Management
New York
$16K – – –
CS
33
Cannell & Spears
New York
$16K – – –
GSEP
34
Golden State Equity Partners
California
$16K +$1.08K +110 +5%
Citigroup
35
Citigroup
New York
$14K +$17.7K +1,806 +1,557%
RE
36
RBC Europe
United Kingdom
$14K +$18.1K +1,850 +1,850%
TRCT
37
Tower Research Capital (TRC)
New York
$12K -$22.2K -2,269 -57%
VPIM
38
Vanguard Personalized Indexing Management
California
$12K +$15.9K +1,626 New
Two Sigma Advisers
39
Two Sigma Advisers
New York
$11K -$170K -17,380 -92%
BFM
40
Boothbay Fund Management
New York
$11K – – –
IIA
41
IPG Investment Advisors
California
$10K – – –
Wells Fargo
42
Wells Fargo
California
$9K +$11.3K +1,150 +1,150%
LG
43
Lane Generational
Massachusetts
$8K -$5K -510 -32%
IAA
44
Ironsides Asset Advisors
North Carolina
$8K – – –
RPCA
45
Running Point Capital Advisors
California
$8K +$10.5K +1,070 New
OC
46
Oppenheimer & Co
New York
$8K +$11.4K +1,160 New
UBS Group
47
UBS Group
Switzerland
$7K -$9.48K -968 -52%
US Bancorp
48
US Bancorp
Minnesota
$7K +$3.5K +357 +63%
CWM
49
Connecticut Wealth Management
Connecticut
$7K +$9.8K +1,000 New
APA
50
American Portfolios Advisors
New York
$4.54K – – –
1
2
3 4

ORTX Hedge Fund Activity: Q1 2022 in Review

61 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q1 2022, worth a combined $38.9M — down 54% from $84.6M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ORTX and 8 opened new positions — a net loss of 10 holders — while 16 trimmed existing stakes and 14 added.

The largest buyer was SG Americas Securities, adding an estimated $395K. The largest seller was Artisan Partners, cutting an estimated $4.39M.

  • 61 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q1 2022, down from 72 in Q4 2021.
  • Funds reported $38.9M of Orchard Therapeutics plc American Depositary Shares stock for Q1 2022, down 54% quarter-over-quarter.
  • 8 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q1 2022 and 18 closed out, a net change of -10 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q1 2022 was SG Americas Securities, an estimated $395K added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q1 2022 was Artisan Partners, an estimated $4.39M sold.

Based on aggregated 13F filings for Q1 2022.